Salahuddin A Z, Alam M R, Hossain R M, Feroz S, Zannat H, Mondal M C, Roy A S, Robbani M G, Uddin M B, Kadir M S
Dr Abu Zafor Md Salahuddin, Registrar, Department of Nephrology, Mymensingh Medical College Hospital, Mymensingh, Bangladesh; E-mail:
Mymensingh Med J. 2019 Jul;28(3):527-535.
Renal involvement may be the presenting feature in a vast majority of patients with multiple myeloma and is one of the key for clinical manifestations of symptomatic multiple myeloma. The purpose of the study was to find out the pattern of renal involvement at the time of presentation of multiple myeloma and to explore its association with clinical, laboratory and pathologic features of these cases. This cross sectional study was conducted in the Department of Nephrology at Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh from February 2016 to September 2017. Forty seven (47) patients of newly diagnosed multiple myeloma having renal involvement were included in the study. Multiple myeloma was diagnosed as per criteria proposed by the International Myeloma Working Group, 2003. Renal involvement was considered to be present when any one of proteinuria, microscopic haematuria, renal impairment or urinary tract infection (UTI) was found in the patient. Renal biopsy was done in suitable patients under ultrasound guidance after taking informed written consent. The pattern of renal involvement was detected and status of renal function was assessed and its clinical, laboratory and pathologic associations were analyzed. Data were managed by using computer based software, the Statistical Package for Social Sciences (SPSS) version 23 (IBM Corp.). Median age at presentation was 59 years with the range of 37-76 years. Female (53.2%) was slightly predominant than male (46.8%) and male to female ratio was 1:1.14. Renal impairment, microscopic haematuria, proteinuria, nephrotic range proteinuria, urinary Bence Jones protein and UTI were found in 70%, 19%, 79%, 25%, 19% and 17% of patients respectively. Median serum creatinine and proteinuria were 256μmol/l and 1.24gm/day. Hypercalcaemia and Bence Jones proteinuria were detected in 36% and 27% of patients respectively with renal impairment which were statistically significant. The precipitating factors for renal impairment were NSAIDs use (67%), hyperuricaemia (49%), hypercalcaemia (36%), dehydration (27%), UTI (18%) and no identifiable factor (3%). Dialysis was required in 15% new myeloma patient. Renal biopsy and histopathological examination revealed myeloma cast nephropathy (30%), amyloidosis (30%), glomerulosclerosis (chronic kidney disease) (20%), monoclonal immunoglobulin deposition disease (MIDD) (10%) and interstitial nephritis with fibrosis (10%). Renal involvement was a common and severe complication of multiple myeloma. Renal impairment was strongly associated with hypercalcaemia, NSAIDs use, hyperuricaemia, Bence Jones proteinuria etc.
在绝大多数多发性骨髓瘤患者中,肾脏受累可能是首发特征,也是有症状的多发性骨髓瘤临床表现的关键之一。本研究的目的是找出多发性骨髓瘤初诊时肾脏受累的模式,并探讨其与这些病例的临床、实验室和病理特征之间的关联。这项横断面研究于2016年2月至2017年9月在孟加拉国达卡的班加班杜·谢赫·穆吉布医科大学(BSMMU)肾脏病科进行。47例新诊断的伴有肾脏受累的多发性骨髓瘤患者纳入本研究。多发性骨髓瘤根据国际骨髓瘤工作组2003年提出的标准进行诊断。当患者出现蛋白尿、镜下血尿、肾功能损害或尿路感染(UTI)中的任何一项时,即认为存在肾脏受累。在获得知情书面同意后,对合适的患者在超声引导下进行肾活检。检测肾脏受累模式,评估肾功能状态,并分析其临床、实验室和病理相关性。数据使用基于计算机的软件社会科学统计包(SPSS)23版(IBM公司)进行管理。初诊时的中位年龄为59岁,范围为37 - 76岁。女性(53.2%)略多于男性(46.8%),男女比例为1:1.14。肾功能损害、镜下血尿、蛋白尿、肾病范围蛋白尿、尿本周氏蛋白和UTI分别在70%、19%、79%、25%、19%和17%的患者中发现。血清肌酐和蛋白尿的中位数分别为256μmol/l和1.24gm/天。分别在36%和27%的肾功能损害患者中检测到高钙血症和本周氏蛋白尿,差异有统计学意义。肾功能损害的诱发因素为使用非甾体抗炎药(NSAIDs)(67%)、高尿酸血症(49%)、高钙血症(36%)、脱水(27%)、UTI(18%)和无明确因素(3%)。15%的新诊断骨髓瘤患者需要透析。肾活检和组织病理学检查显示骨髓瘤管型肾病(30%)、淀粉样变性(30%)、肾小球硬化(慢性肾脏病)(20%)、单克隆免疫球蛋白沉积病(MIDD)(10%)和伴有纤维化的间质性肾炎(10%)。肾脏受累是多发性骨髓瘤常见且严重的并发症。肾功能损害与高钙血症、使用NSAIDs、高尿酸血症、本周氏蛋白尿等密切相关。